Inspiration Biopharmaceuticals

About:

Inspiration Biopharmaceuticals develops recombinant blood coagulation factor products for the treatment of hemophilia.

Website: http://www.inspirationbio.com

Twitter/X: InspirationBio

Description:

Inspiration Biopharmaceuticals, Inc. develops recombinant blood coagulation factor products for the treatment of hemophilia. Its product candidates include IB1001, an intravenous recombinant factor IX for the acute and preventative treatment of bleeding in individuals with hemophilia B; and OBI-1, an intravenous recombinant porcine factor VIII (FVIII) for the treatment of individuals who have developed inhibitors against human FVIII and for individuals with acquired hemophilia A. The company also has preclinical programs that focus on human recombinant factor VIIa for individuals with either hemophilia A or B who have developed inhibitors, and individuals with factor VII deficiency; human recombinant FVIII to treat individuals with hemophilia A. Inspiration Biopharmaceuticals has a strategic partnership with Ipsen SA. The company was founded in 2004 and is based in Laguna Niguel, California.

Total Funding Amount:

$259M

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

Laguna Niguel, California, United States

Founded Date:

2004-01-01

Contact Email:

helpdesk(AT)inspirationbio.com

Founders:

Scott Martin

Number of Employees:

51-100

Last Funding Date:

2011-03-29

IPO Status:

Private

Industries:

© 2025 bioDAO.ai